Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCHP vs EC-THP Neoadjuvant Treatment in HER2-Positive Breast Cancer
NCT04094896Phase 2Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2019
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, carboplatin, trastuzumab, pertuzumab in HER2-positive breast cancer, sponsored by Guangdong Provincial People's Hospital. Status: unknown.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04094896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094896.